

Organization Background



MemorialCare's Commitment to Accessible Value-Based Ambulatory Network

ACO Health Plan Partnerships

Value Based Products	Descriptors
 offered by 	<ul style="list-style-type: none">• Commercial HMO
 	<ul style="list-style-type: none">• Commercial PPO
	<ul style="list-style-type: none">• Commercial PPO
	<ul style="list-style-type: none">• Commercial PPO
	<ul style="list-style-type: none">• Direct Contract with Boeing, PPO



*MemorialCare
is in more value-based
products than any other
health system in Southern
California.*

*260,000 at-risk lives
including Senior &
Commercial HMO*

Biosimilar lessons learned so far

1. Biosimilars act like competing branded drugs, not like traditional brand and generic drugs. Thus, the approach and expectations with biosimilars are different.
2. Biosimilars are a tool in the specialty drug management toolbox.
 - If we do not use biosimilars, the pipeline will dry up.
3. The need for transparency around drug costs is applicable to biosimilars and reference products.
4. HMO and ACO experience



**Dr. Kimberly Tsai,
Managed Care Pharmacist Supervisor
MemorialCare Medical Foundation**

Dr. Kimberly Tsai has spent the last decade working in managed care pharmacy and is currently the Managed Care Pharmacist Supervisor with MemorialCare Medical Foundation, located in Southern California. She leads the specialty drug strategy within the provider groups, MemorialCare Medical Group and Greater Newport Physicians independent practice association. She serves as the pharmacy subject matter expert on oncology, biosimilars, and specialty drugs. She has been with the company over 6 years.

Dr. Tsai was previously a Clinical Pharmacist at OptumRx, where she was responsible for quarterly company-wide drug pipeline presentations. She supported the Pharmacy and Therapeutics committee with writing and presenting monographs and prior authorization guidelines. She was also responsible for provider and patient education on breaking clinical news.